. Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study. Dement Geriatr Cogn Disord. 2010;30(2):131-46. PubMed.


Please login to recommend the paper.


Comments on this Paper

No Available Comments

Make a Comment

To make a comment you must login or register.

This paper appears in the following:


  1. Trial Updates: B Vitamin Back in Vogue? Diabetes Drug Less Sweet